Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives
Glioblastoma (GBM) is a primary neuroepithelial tumor of the central nervous system, characterized by an extremely aggressive clinical phenotype. Patients with GBM have a poor prognosis and only 3–5% of them survive for more than 5 years. The current GBM treatment standards include maximal resection...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2017-01-01
|
| Series: | BioMed Research International |
| Online Access: | http://dx.doi.org/10.1155/2017/8013575 |